Neoleukin Therapeutics (NLTX) Competitors $15.00 +1.97 (+15.12%) As of 04/30/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock NLTX vs. TRML, MNMD, DNA, SIGA, VERV, PGEN, MAZE, PRTC, ABVX, and AUTLShould you be buying Neoleukin Therapeutics stock or one of its competitors? The main competitors of Neoleukin Therapeutics include Tourmaline Bio (TRML), Mind Medicine (MindMed) (MNMD), Ginkgo Bioworks (DNA), SIGA Technologies (SIGA), Verve Therapeutics (VERV), Precigen (PGEN), Maze Therapeutics (MAZE), PureTech Health (PRTC), ABIVAX Société Anonyme (ABVX), and Autolus Therapeutics (AUTL). These companies are all part of the "pharmaceutical products" industry. Neoleukin Therapeutics vs. Tourmaline Bio Mind Medicine (MindMed) Ginkgo Bioworks SIGA Technologies Verve Therapeutics Precigen Maze Therapeutics PureTech Health ABIVAX Société Anonyme Autolus Therapeutics Tourmaline Bio (NASDAQ:TRML) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, community ranking, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations. Which has higher earnings & valuation, TRML or NLTX? Tourmaline Bio is trading at a lower price-to-earnings ratio than Neoleukin Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTourmaline BioN/AN/A-$42.12M-$2.87-5.88Neoleukin TherapeuticsN/AN/A-$57.56M-$3.11-4.82 Which has more volatility & risk, TRML or NLTX? Tourmaline Bio has a beta of 2.14, indicating that its share price is 114% more volatile than the S&P 500. Comparatively, Neoleukin Therapeutics has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Does the MarketBeat Community believe in TRML or NLTX? Neoleukin Therapeutics received 28 more outperform votes than Tourmaline Bio when rated by MarketBeat users. However, 100.00% of users gave Tourmaline Bio an outperform vote while only 45.87% of users gave Neoleukin Therapeutics an outperform vote. CompanyUnderperformOutperformTourmaline BioOutperform Votes22100.00% Underperform VotesNo VotesNeoleukin TherapeuticsOutperform Votes5045.87% Underperform Votes5954.13% Do analysts rate TRML or NLTX? Tourmaline Bio currently has a consensus price target of $49.33, indicating a potential upside of 192.45%. Given Tourmaline Bio's stronger consensus rating and higher probable upside, research analysts clearly believe Tourmaline Bio is more favorable than Neoleukin Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tourmaline Bio 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media refer more to TRML or NLTX? In the previous week, Tourmaline Bio had 11 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 12 mentions for Tourmaline Bio and 1 mentions for Neoleukin Therapeutics. Tourmaline Bio's average media sentiment score of 1.12 beat Neoleukin Therapeutics' score of 0.00 indicating that Tourmaline Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tourmaline Bio 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neoleukin Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders hold more shares of TRML or NLTX? 91.9% of Tourmaline Bio shares are held by institutional investors. Comparatively, 52.4% of Neoleukin Therapeutics shares are held by institutional investors. 11.0% of Tourmaline Bio shares are held by company insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is TRML or NLTX more profitable? Tourmaline Bio's return on equity of -20.97% beat Neoleukin Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Tourmaline BioN/A -20.97% -20.56% Neoleukin Therapeutics N/A -37.22%-30.91% SummaryTourmaline Bio beats Neoleukin Therapeutics on 13 of the 15 factors compared between the two stocks. Get Neoleukin Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NLTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NLTX vs. The Competition Export to ExcelMetricNeoleukin TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$140.97M$6.72B$5.49B$7.97BDividend YieldN/A3.05%5.11%4.23%P/E Ratio-4.827.3622.6118.58Price / SalesN/A241.71397.51103.15Price / CashN/A65.8538.1834.62Price / Book1.356.486.704.26Net Income-$57.56M$143.43M$3.22B$248.31M7 Day Performance-2.85%1.69%1.26%1.34%1 Month Performance28.10%6.58%3.73%3.92%1 Year Performance-56.50%-2.63%15.82%5.33% Neoleukin Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NLTXNeoleukin TherapeuticsN/A$15.00+15.1%N/A-61.0%$140.97MN/A-4.8290High Trading VolumeTRMLTourmaline Bio2.6994 of 5 stars$16.76+4.7%$45.20+169.7%+8.7%$430.48MN/A-5.9444Analyst RevisionMNMDMind Medicine (MindMed)2.3177 of 5 stars$5.66-1.9%$25.11+343.7%-32.9%$426.58MN/A-2.5040Upcoming EarningsDNAGinkgo Bioworks0.596 of 5 stars$7.35-6.4%$4.58-37.8%-79.3%$426.55M$227.04M-0.56640Upcoming EarningsNews CoverageSIGASIGA Technologies1.8594 of 5 stars$5.97-0.3%N/A-37.1%$426.48M$138.72M4.9840Upcoming EarningsOptions VolumePositive NewsVERVVerve Therapeutics3.7286 of 5 stars$4.78+4.1%$25.75+438.7%-5.7%$424.45M$32.33M-1.94110Positive NewsHigh Trading VolumePGENPrecigen3.6771 of 5 stars$1.37-1.4%$7.00+410.9%+18.2%$408.72M$3.93M-2.49190News CoveragePositive NewsMAZEMaze TherapeuticsN/A$9.13+8.6%$25.67+181.1%N/A$399.86M$167.50M0.00121PRTCPureTech Health2.1948 of 5 stars$16.64-0.6%$45.00+170.5%-38.1%$399.56M$3.33M0.00100News CoverageABVXABIVAX Société Anonyme2.3916 of 5 stars$6.23-2.7%$38.00+510.0%-52.5%$395.10MN/A0.0061Analyst ForecastNews CoveragePositive NewsAUTLAutolus Therapeutics2.7213 of 5 stars$1.44+0.7%$9.32+547.2%-61.7%$383.18M$10.12M-1.19330Upcoming EarningsPositive NewsGap Down Related Companies and Tools Related Companies Tourmaline Bio Alternatives Mind Medicine (MindMed) Alternatives Ginkgo Bioworks Alternatives SIGA Technologies Alternatives Verve Therapeutics Alternatives Precigen Alternatives Maze Therapeutics Alternatives PureTech Health Alternatives ABIVAX Société Anonyme Alternatives Autolus Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NLTX) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neoleukin Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neoleukin Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NLTX Stock Free NLTX Stock Alerts